Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.42 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074420 | 1.00 | CYP1A2 (0.51) | CYP1A2PPARGPPARACNR2LMNA | |
| SCHEMBL3074423 | 1.00 | CYP1A2 (0.51) | CYP1A2PPARGPPARACNR2LMNA | |
| SCHEMBL3074422 | 1.00 | CYP1A2 (0.51) | CYP1A2PPARGPPARACNR2LMNA | |
| SCHEMBL3062673 | 0.85 | PPARG (0.52) | CYP1A2PPARGPPARAHDAC3HDAC1 | |
| SCHEMBL11988779 | 0.85 | PPARG (0.52) | CYP1A2PPARGPPARAHDAC3HDAC1 | |
| SCHEMBL3062675 | 0.85 | PPARG (0.52) | CYP1A2PPARGPPARAHDAC3HDAC1 | |
| SCHEMBL5693157 | 0.83 | CNR2 (0.43) | CYP1A2PPARGPPARACNR2LMNA | |
| SCHEMBL5693154 | 0.83 | CNR2 (0.43) | CYP1A2PPARGPPARACNR2LMNA | |
| SCHEMBL11988773 | 0.81 | RAB9A (0.47) | PPARGPPARACNR2LMNAMAPT | |
| SCHEMBL3070948 | 0.80 | CYP1A2 (0.53) | CYP1A2CNR2LMNAHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247448-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2012-08-21 | — | — | US | claimed |
| US-7820847-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2010-10-26 | — | — | US | claimed |
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ZEILLER JEAN-JACQUES | 2010-10-14 | — | — | US | claimed |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2006-08-10 | — | — | US | claimed |
| EP-1658260-A1 | BUTENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USE FOR THE TREATMENT OF DYSLIPIDAEMIA, ATHEROSCLEROSIS AND DIABETES | Merk Patent Gmbh (DE) | 2006-05-24 | — | — | EP | claimed |
| WO-2005014521-A1 | BUTENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USE FOR THE TREATMENT OF DYSLIPIDAEMIA, ATHEROSCLEROSIS AND DIABETES | MERK PATENT GMBH (DE) | 2005-02-17 | — | — | WO | claimed |
| US-8247448-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2012-08-21 | — | — | US | disclosed |
| US-7820847-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ZEILLER JEAN-JACQUES | 2010-10-14 | — | — | US | disclosed |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261789-A1 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | ALOX15, LIPA, APOB | CYP1A2 369/4885PPARG 130/4885PPARA 75/4885 |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | APOB, ALOX15, GPR119 | CYP1A2 414/4885PPARG 136/4885PPARA 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.